Entities / Company
Savara (Denmark).
company in Hørsholm, Denmark
- Reports this week
- 0
- Active events
- 0
- Connections
- 23
What's happening
Gone quiet
No new reports in 90+ days-
Savara's lead program is under FDA review, and the company uses LinkedIn for its professional presence.Some support1 report
-
Savara Inc. announced that its product, Molgramostim, successfully treats Autoimmune Pulmonary Alveolar Proteinosis, based on trial results published in the New England Journal of Medicine.Some support1 report
-
FDA reached an agreement on CMC data requirements for Savara, while Fujifilm Diosynth Biotechnologies announced a change in drug substance manufacturer.Some support1 report
-
Savara (Denmark) reported higher prevalence of Autoimmune Pulmonary Alveolar Proteinosis based on updated claims data analysis.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Savara (Denmark) this week
News at the entities that move Savara (Denmark) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Savara (Denmark)
-
Food and Drug Administration StructuralIn 2007, CBS broadcast featured Andrews, Cordes, and Couric criticizing the Food and Drug Administration's problems.Moves Savara (Denmark)
Connections
The 3 strongest of 23, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Savara is subject to the formal regulatory review and approval process administered by the FDA.
-
Food and Drug Administration Structural
The FDA reviewed Savara's biologics license application and issued a refusal to file letter.
-
Alena Kohušová Mentioned together
No direct relationship evidence found in the provided snapshots.
History
Events by the month they beganJune 2026
4 events- Savara's lead program is under FDA review, and the company uses LinkedIn for its professional presence.
- Savara Inc. announced that its product, Molgramostim, successfully treats Autoimmune Pulmonary Alveolar Proteinosis, based on trial results published in the New England Journal of Medicine.
- FDA reached an agreement on CMC data requirements for Savara, while Fujifilm Diosynth Biotechnologies announced a change in drug substance manufacturer.
- Savara (Denmark) reported higher prevalence of Autoimmune Pulmonary Alveolar Proteinosis based on updated claims data analysis.